Sažetak
Uvod. Primarna mijelofibroza je klonsko mijeloproliferativno oboljenje koje se najčeščće javlja u šestoj deceniji života, a vrlo retko kod mladih osoba. Prikaz bolesnika. Prikazana je 28-godišnja bolesnica sa primarnom mijelofibrozom, koja je imala normalnu trudnoću i porođaj u četrdesetoj nedelji trudnoće bez komplikacija. Tokom cele trudnoće bolesnica je lečena interferonom alfa i niskim dozama aspirina, a nedelju dana pre i 6 nedelja nakon porođaja primenjen je i niskomolekularni heparin u profilaktičkim dozama. Bolesnica nije imala komplikacije tokom trudnoće i rodila je zdravu bebu normalne težine. Zaključak. Odluka o strategiji lečenja trudnica sa prisutnim hematološkim malignitetima treba da bude doneta posebno za svaku bolesnicu.
Ključne reči
Array
Array
Array
Array
Array
Array
Array
Array
Array
Array
Reference
Swerdlow SH, Campo E, Harris NL, Jaffe, ES, Pileri, SA, Stein, H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008.
Tefferi A. Primary myelofibrosis: 2012 update on diagnosis, risk stratification and management. Am J Hematol 2011; 86(12): 1017−26.
Griesshammer M, Struve S, Barbui T. Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. Blood Rev 2008; 22(5): 235−45.
McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the U.K. Hema-tol Oncol 1997; 15(4): 173−89.
Taylor UB, Bardeguez AD, Iglesias N, Gascon P. Idiopathic mye-lofibrosis in pregnancy: a case report and review of the litera-ture. Am J Obstet Gynecol 1992; 167(1): 38−9.
Gotić M, Cvetković M, Bozanović T, Cemerikić V. Successful treatment of primary myelofibrosis with thrombocytosis dur-ing pregnancy with alfa-interferon. Srp Arh Celok Lek 2001; 129(11−12): 304−8.
Tulpule S, Bewley S, Robinson SE, Radia D, Nelson-Piercy C, Harrison CN. The management and outcome of four pregnancies in women with idiopathic myelofibrosis. Br J Haemat 2008; 142(3): 480−2.
Randi ML, Rossi C, Fabris F, Girolami A. Essential thrombo-cythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 pa-tients. Clin Appl Thromb Hemost 2000; 6(1): 31−5.
Bai Y, Zhang C, Wang J, Liang M, Zhang X. Clinical analysis of eleven patients with chronic myeloproliferative disorders com-plicating pregnancy. Zhonghua Fu Chan Ke Za Zhi 2010; 45(12): 896−9.
Yazdani Brojeni P, Matok I, Garcia BF, Koren G. A systematic re-view of the fetal safety of interferon alpha. Reprod Toxicol 2012; 33(3): 265−8.
Melillo L, Tieghi A, Candoni A, Radaelli F, Ciancia R, Specchia G, et al. Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry. Am J Heamtol 2009; 84(10): 636−40.
Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol 2005; 129(3): 293−306.
Robin M, Tabrizi R, Mohty M, Furst S, Michallet M, Bay J, et al. Allogeneic haematopoietic stem cell transplantation for mye-lofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Br J Haematol 2011; 152(3): 331−9.
Messa RA. New drugs for the treatment of myelofrosis. Curr Hematol Malig Rep 2010; 5(1): 15−21.
Vannucchi AM. Management of myelofibrosis. Hematology Am Soc Hematol Educ Program 2011; 2011: 222−30.
Hasselbalch HC. A new era for IFN-α in the treatment of Phila-delphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol 2011; 4(6): 637−55.